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Significance of epidermal mitoses
in challenging melanocytic
proliferations
Background: Accurate diagnosis of melanoma remains
histologically challenging. Dermal mitoses support malignancy,
but are only occasionally seen in melanomas. As melanomagenesis
is thought to begin at the dermal-epidermal junction, we
investigated the significance of epidermal melanocytic mitoses
(EMM) in a spectrum of lesions with molecular characterization.
Methods: Epidermal mitoses density (EMD) was evaluated in 46
straightforward lesions (24 benign and 22 malignant) and 30
challenging lesions with expert interpretation, fluorescence in
situ hybridization and myPath-score characterization (12
favor-benign, 9 favor-malignant and 9 ambiguous). EMD was
correlated with clinicopathologic parameters and myPath.
Results: In straightforward cases, 25% nevi and 77% melanomas
had EM. Median EMD was significantly lower in nevi vs.
melanomas (0/mm vs. 0.04/mm, p= 0.001). EMD
(0.01/mm-cutoff) had 77% sensitivity, 79% specificity
discriminating melanomas from nevi. In challenging cases, 17%
favor-benign, 67% favor-malignant and 78% ambiguous lesions
had EM. EMD (0.01/mm-cutoff) had 67% sensitivity, 82%
specificity on 21 non-ambiguous lesions, similar to myPath. EMD
was less accurate in Spitzoid lesions, which have high EMD and
dermal mitoses.
Conclusion: While EMD is not an adequate single criterion in
diagnosing melanoma, our results validate its discriminatory
potential, suggesting that EM should prompt closer investigation
for malignancy. Expanded studies with clinical follow up are
warranted to further assess the EM utility in classifying
melanocytic lesions.
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Melanoma is the most life threatening form
of skin cancer,1 yet it can be the most difficult
to diagnose on histopathologic parameters.2–6
There are various morphologic mimickers
of melanoma including nevi with high-grade
dysplasia and Spitz tumors,7,8 and melanomas
can occur in a broad age distribution.9 Thus,
there exists a group of melanocytic prolifera-
tions in which definitive classification as benign
or malignant either cannot be made with cer-
tainty, or requires the use of ancillary, including
molecular tests.
Criteria to distinguish melanoma have tra-
ditionally been divided into architectural and
cytologic.10 Many of the architectural criteria
used to diagnose melanoma – pagetoid spread
of melanocytes, lentiginous growth, bridging of
rete ridge nests and misplaced/misshaped nests
overlap to varying degrees with dysplastic nevi.
Cytologic features used to classify melanoma
such as cellular enlargement, prominent nucle-
oli and reduced maturation can be seen in Spitz
nevi. Dermal mitotic figures are somewhat rare
(0–15% based on numerous studies) in benign
nevi, and when combined with other histologic
features of melanoma, are quite consistent with
the diagnosis.11 This is related to the fact that
most benign melanocytic lesions decrease pro-
liferation and enter senescence once in the
inhospitable environment of the dermis.12 Nev-
ertheless, most early melanomas do not show
dermal mitotic figures, hence this criterion may
be of no aid in the discrimination of thin or bor-
derline melanocytic proliferations.
Table 1. Case distribution based on histopathologic interpretation
ALM, acral lentiginous melanoma; AMP, atypical melanocytic proliferation; AST, atypical Spitz tumor; LMM, lentigo maligna melanoma; SSM,
superficial spreading melanoma.
Melanomagenesis takes place at the
dermal-epidermal junction,12 and yet the
significance of epidermal mitotic figures in
challenging melanocytic proliferations has not
been systematically evaluated. Here, we have
assessed and quantified epidermal melanocytic
mitoses in a cohort of histologically straightfor-
ward, and histologically difficult melanocytic
lesions with molecular characterization [myPath
gene expression score (Myriad Genetics, Salt
Lake City, UT, USA) and fluorescence in situ
hybridization (FISH)] and expert consensus
diagnosis. The presence and density of epider-
mal melanocytic mitoses was correlated with
several clinicopathologic parameters and the
myPath score.
Materials and methods
Following Institutional Review Board (IRB)
approval, a total of 76 junctional or compound
melanocytic lesions previously diagnosed at our
institution, were evaluated for the presence
of epidermal mitoses. The cases comprised
46 straightforward lesions and 30 challenging
lesions (Table 1). The straightforward cases were
diagnosed by the primary dermatopathologist
on histologic basis only, and included 24 benign
dysplastic nevi (16 moderate dysplasia and 8
severe dysplasia) and 22 melanomas (8 in situ,
12 superficial spreading melanoma, 1 lentigo
maligna melanoma and 1 acral lentiginous
melanoma). The challenging cases were diag-
nosed after expert consensus (JSK, SDB, MTT
and AAA) and analysis by melanoma-FISH using
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Vysis Melanoma FISH Probes (Abbott Molecular,
Des Plaines, IL, USA) for 6p25 (RREB1), CEP6,
6q23 (MYB), 11q13 (CCND1), 8q24 (MYC),
9p21 (CDKN2A) and CEP9 (centromeric ref-
erence). The final pathologic interpretation
was favor-benign in 12 cases (2 spitzoid, 1
non-dysplastic and 9 dysplastic), ambiguous
in 9 cases [6 atypical Spitz tumor (AST), 3
atypical melanocytic proliferation (AMP)] and
favor-malignant in 9 cases.
All 46 straightforward cases and 28 of the 30
challenging cases were also characterized with
myPath gene expression score (Myriad Genetic
Laboratories).
Epidermal melanocytic mitosis were identi-
fied and distinguished from keratinocyte mitoses
based on the location within a melanocytic nest,
the quality of the cytoplasm and the lack of cell
adhesion structures. The epidermalmitoses were
normalized for the amount of tissue present for
evaluation as follows: the total number of epider-
mal mitoses counted on all levels of all sections
available for each lesion was divided by the num-
ber of levels and the measured junctional com-
ponent length in millimeters (mm). The result
expressed the density of epidermal mitoses/mm
length for each lesion (epidermalmitotic density
or EMD).
Other histologic parameters recorded were
the Breslow’s depth and number of dermal
melanocytic mitoses (for melanomas only) and
the presence of associated inflammation, either
in the form of chronic inflammatory infiltrates
involving the melanocytic proliferations or
as incidental chronic folliculitis. None of the
lesions showed significant acute inflammation.
Statistical comparisons were made between the
presence of epidermal mitoses or EMD and
multiple clinicopathologic parameters includ-
ing: patient age and sex, anatomic location of the
lesion, histologic diagnosis, presence of inflam-
mation, Breslow’s depth (for melanomas only)
and myPath score. To derive p values, Fisher’s
exact test and chi-square test were used for
categorical data, whereas Wilcoxon rank sum
test and Kruskal-Wallis test were used for mea-
sured data.
Results
Epidermal mitoses in straightforward dysplastic nevi
and melanomas
Clinicopathologic features and mitotic prevalence
The clinicopathologic characteristics of the 46
straightforward cases are listed in Table S1, Sup-
porting Information and summarized in Table 2.
Table 2. Statistical analysis of clinicopathologic features in the
straightforward case group
Benign Malignant
Median
(range)
or N (%)
Median
(range)
or N (%) p
Age 51 (22–91) 61 (20–91) 0.02
Sex
Female 9 (38%) 5 (23%)
Male 15 (62%) 17 (77%) 0.35
Site
Arm/leg/foot 11 (46%) 4 (18%)
Trunk 13 (54%) 13 (59%)
Head 0 5 (23%) 0.02
Inflammation
No 10 (42%) 7 (32%)
Yes 14 (58%) 15 (68%) 0.55
Epidermal mitoses (total) 0 (0–5) 1.0 (0–24) 0.001
No. levels 6 (1–17) 4 (1–15) 0.27
EMD 0 (0–0.10) 0.04 (0–0.32) 0.001
EMD >0.01
No 19 (79%) 5 (23%)
Yes 5 (21%) 17 (77%) 0.0003
myPath group
Benign (<−2.0) 19 (79%) 2 (9%)
Indeterminate (−2.0 to 0) 5 (21%) 4 (18%)
Malignant (≥0) 0 16 (73%) <0.0001
EMD, epidermal mitotic density.
Representative images of a dysplastic nevus and
a melanoma with epidermal melanocytic mitoses
are shown in Fig. 1. Statistically significant dif-
ferences in clinical parameters between patients
with benign vs. malignant lesions included
median age (51 vs. 61, p= 0.02) and frequency
lesions on extremities (46% vs. 18%, p= 0.02).
There was no significant difference in sex or
presence of inflammation (Table 2).
Of 24 benign dysplastic nevi, 6 (25%) nevi
(5 moderate dysplasia and 1 severe dysplasia)
showed one or more epidermal mitoses (median
2, range 1–5) with a median EMD of 0/mm
(range 0–0.10/mm). No dermal mitoses were
seen. There was no significant difference in
patient age or sex for dysplastic nevi with epi-
dermal mitoses (median age 48.5; M : F= 1 : 1)
and nevi without epidermal mitoses (median age
52, p= 0.56; M : F= 2 : 1, p= 0.63). There was
also no difference in the anatomic location of the
nevi with epidermalmitoses (trunk 3/6, 50%; leg
2/6, 33%; arm 1/6, 17%) and without epidermal
mitoses (trunk 10/18, 56%; leg 4/18, 22%; arm
4/18, 22%). Chronic inflammation was present
in 4 of 6 (67%) nevi with epidermal mitoses
and in 10 of 18 (56%) nevi without mitoses
(p= 0.5).
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Fig. 1. Representative images of unequivocal benign and malignant lesions with epidermal melanocytic mitoses (arrows): dysplastic
nevus (A) ×100, (B) ×400; melanoma (C) ×100, (D) ×400.
Of 22 melanomas, 17 (77%) showed one
or more epidermal mitoses (median 2, range
1–24) with a median EMD of 0.04/mm (range
0–0.32/mm), significantly higher than that
in benign nevi (p= 0.001) (Fig. 2A). Five
melanomas showed no epidermal mitoses (three
in situ, one LMM and one SSM). Of the 14 inva-
sive melanomas, only 4 had dermal mitoses
(median 1.5/mm2, range 1–5/mm2), while 12
of 14 had epidermal mitoses (median 0.06/mm,
range 0.02–0.32/mm). Interestingly, the EMD
(mitoses/mm) showed a good correlation with
the Breslow’s thickness (mm) for all invasive
melanomas (r= 0.79; Fig. 2B). There was no sig-
nificant difference in patient age for melanomas
with epidermal mitoses (median age 59) and
melanomas without epidermal mitoses (median
age 76; p= 0.37). Although all five melanomas
without epidermal mitoses were in men, the
sample size was too small for a meaningful
comparison. There was also no difference in the
anatomic location of melanomas with epidermal
mitoses (trunk 9/17, 53%; head/neck 4/17,
23%; arm 2/17, 12%; leg 1/17, 6%; acral 1/17,
6%) and without epidermal mitoses (trunk 4/5,
80%; head 1/5, 20%). Chronic inflammation
or folliculitis was present in 12 of 17 (71%)
melanomas with epidermal mitoses and in 3
of 5 (60%) melanomas without mitoses (no
significant difference, p= 1).
Discriminatory power of epidermal mitoses
By applying a recursive portioning algorithm, an
EMD cutoff of 0.01 mitoses/mm was calculated
to best separate benign and malignant lesions.
With this cutoff, EMD shows a sensitivity of
77% and a specificity of 79% in distinguishing
straightforward melanomas from nevi (Fig. 2A,
Table 2). Phenotypic characterization by myPath
gene expression score was available on all of
the cases in this cohort, as a discriminatory
standard. Here, the gene expression score was
concordant with the histologic diagnosis in 16
of 22 melanomas (73% sensitivity) and 19 of
24 dysplastic nevi (79% specificity) (Table 2). It
was indeterminate in 5 of 24 (21%) nevi and
4 of 22 (18%) melanomas and discordant in
2 of 22 (9%) melanomas. The myPath score
showed a weak correlation with the Breslow’s
thickness (r= 0.23) on 14 invasive melanomas.
It did not show a significant correlation with
the patient age, sex, body site or presence of
inflammation. Overall, for the straightforward
lesions, EMD (cutoff 0.01) was non-inferior to
myPath in distinguishing benign frommalignant
lesions. When using a combined test approach,
where a ‘positive’ result was considered if either
EMD was >0.01 or myPath was positive in any
combination with the other test’s result, the
sensitivity in detecting melanomas increased to
95% with 79% specificity.
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Fig. 2. Distribution of epidermal mitotic density (EMD) in
straightforward benign and malignant lesions (A) with a cutoff
of 0.01/mm (median EMD on top). Correlation between
EMD and Breslow’s thickness on 14 straightforward invasive
melanomas (B) (rS Spearman non-parametric coefficient).
Epidermal mitoses in challenging/borderline melanocytic
proliferations
Clinicopathologic features and mitotic prevalence
The clinicopathologic characteristics of the
30 challenging cases are listed in Table S2
and summarized in Table 3. Representative
images of a Spitz nevus and an AST with
epidermal melanocytic mitoses are shown in
Fig. 3. The sole baseline clinicopathologic fea-
ture which differed significantly between the
favor-benign, ambiguous and favor-malignant
lesions was the presence of inflammation, which
was present in increasing proportions with
increasing histologic grade (17%, 56%, 89%,
respectively; p= 0.004 overall, p= 0.002 between
favor-benign and favor-malignant). There was
no significant difference in patient age, sex or
anatomic location (Table 3). All favor-malignant
lesions hadmolecular confirmation with positive
melanoma-FISH, whereas all favor-benign and
ambiguous lesions were FISH-negative. FISH
results were known to the expert pathologists at
the time of consensus diagnosis.
Epidermal mitoses were present in 2 of 12
(17%) favor-benign lesions (1/10 non-Spitz, 1/2
Spitz; median EMD 0/mm, range 0–0.75/mm),
7 of 9 ambiguous lesions (5/6 AST, 2/3 AMP;
median EMD 0.11/mm, range 0–1.10/mm) and
6 of 9 (67%) favor-malignant lesions (median
EMD 0.04/mm, range 0–0.4/mm) (Fig. 4A).
The difference in median EMD between the
three groups of lesions was statistically signif-
icant (p= 0.03). When isolated as a separate
group, Spitz lesions (favor-benign and ambigu-
ous AST) had by far the highest EMD (median
0.14/mm, range 0–1.1/mm) compared with
the remaining favor-benign non-Spitz lesions
(median 0/mm, range 0–0.11/mm, similar to
that seen in the benign straightforward lesions),
ambiguous AMP lesions (median 0.04/mm,
range 0–0.04/mm) and favor-malignant lesions
(median 0.04/mm, range 0–0.4/mm) (Fig. 4B).
Dermal mitoses were also present in one of two
Spitz nevi and in five of six AST. In comparison,
only two of nine (22%) favor-malignant lesions
had dermal mitoses (median 2/mm2). In this
group of nine favor-malignant lesions, EMD
showed weak correlation with Breslow’s thick-
ness (Fig. 4C, r= 0.43) compared with that seen
with straightforward melanomas.
Including all 30 challenging lesions, there was
no significant difference in patient age or sex
between those with epidermal mitoses (mean
age 51; M : F= 1 : 1.1) and those without epi-
dermal mitoses (mean age 41, p= 0.24; M : F= 2
: 1, p= 0.46). There was also no difference in
the anatomic location of lesions with epidermal
mitoses (trunk 9/15, 60%; arm 3/15, 20%; leg
2/15, 13%; head/neck 1/15, 7%) and without
epidermal mitoses (trunk 8/15, 53%; leg 4/15,
27%; arm 1/15, 7%; head/neck 1/15, 7%; acral
1/15, 7%) (Table 3).
Discriminatory power of epidermal mitoses
EMD with a cutoff of 0.01/mm showed a sensitiv-
ity of 67% and a specificity of 82% in distinguish-
ing the 9 favor-malignant lesions from the 12
favor-benign lesions (Table 3; Fig. 4A). As a com-
parative standard, myPath gene expression scor-
ing was concordant with the histologic diagnosis
in 6 of 9 favor-malignant lesions (67% sensitiv-
ity) and 5 of 11 favor-benign lesions (45% speci-
ficity) (Table 3). In the ambiguous subgroup of
challenging lesions, EMDwould label two of nine
(22%) as benign (one AST, one AMP) and seven
of nine (78%) as malignant (five AST, two AMP)
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Table 3. Statistical analysis of clinicopathologic features in the challenging case group
Favor-benign Ambiguous Favor-malignant
Median (range)
or N (%)
Median (range)
or N (%)
Median (range)
or N (%) p (all groups)
p (benign
vs. malignant)
Age 60 (16–80) 33 (5–56) 57 (18–82) 0.16 0.83
Sex
Female 5 (42%) 6 (67%) 3 (33%)
Male 7 (58%) 3 (33%) 6 (67%) 0.33 1
Site
Arm/leg/foot 4 (33%) 4 (44%) 3 (33%)
Trunk 8 (67%) 3 (33%) 6 (67%)
Head 0 2 (22%) 0 0.19 1
Inflammation
No 10 (83%) 4 (44%) 1 (11%)
Yes 2 (17%) 5 (56%) 8 (89%) 0.004 0.002
EMD 0 (0–0.75) 0.11 (0–1.10) 0.04 (0–0.40) 0.03 0.06
EMD >0.01
No 10 (83%) 2 (22%) 3 (33%)
Yes 2 (17%) 7 (78%) 6 (67%) 0.01 0.03
myPath group
Benign (<−2.0) 5 (45%) 4 (50%) 3 (33%)
Indeterminate (−2.0 to 0) 4 (36%) 2 (25%) 0
Malignant (≥0) 2 (18%) 2 (25%) 6 (67%) 0.14 0.04
EMD, epidermal mitotic density.
Fig. 3. Representative images of challenging lesions with epidermal melanocytic mitoses (arrows): Spitz nevus (A) ×100, (B) ×400;
atypical Spitz tumor (C) ×100, (D) ×400.
based upon the cutoff of 0.01/mm. myPath cat-
egorized four of eight (50%) lesions (three AST,
one AMP) as benign, two of eight (25%) lesions
(one AST, one AMP) as indeterminate and two
of eight (25%) lesions (one AST, one AMP) as
malignant. For one lesion, the test was tech-
nically unsuccessful. While true classification
of these cases may be aided by long-term fol-
low up, overall, patients in this category would
be expected to have excellent survival given
that six of nine cases represent FISH-negative
(including 9p21) AST, and the remaining three
of nine cases of AMP would have Breslow’s
thicknesses of (0.3, 0.5 and 0.6mm). Overall,
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Fig. 4. Distribution of epidermal mitotic density (EMD) in
challenging favor-benign, ambiguous and favor-malignant
lesions (A) with a cutoff of 0.01/mm (median EMD on
top). Similar distribution of EMD when Spitzoid lesions
(favor-benign and ambiguous) are grouped separately
(B). Correlation between EMD and Breslow’s thickness on
nine invasive favor-malignant lesions (C) (rS Spearman
non-parametric coefficient).
excluding ambiguous lesions, EMD (cutoff 0.01)
was again non-inferior to myPath in distinguish-
ing favor-benign from favor-malignant lesions.
When using the same combined EMD-myPath
test approach as described above, the sensitivity
in segregating non-ambiguous lesions increased
to 78% with 73% specificity.
Discussion
Despite the repeated investigation of dermal
mitoses in benign and malignant melanocytic
proliferations,11,13–17 relatively little information
exists in the literature as to the prevalence, fre-
quency and meaning of junctional mitoses in
melanocytic lesions. Indeed, in our experience,
junctional mitoses may be equally rare in typi-
cal banal nevi as compared with dermal mitoses.
We inferred that epidermal mitoses may be bio-
logically significant in melanoma and border-
line lesions. Because melanomagenesis begins
at the dermal-epidermal junction, as manifest
by the propensity of radial growth phase to
precede vertical growth phase, this histologic
sign may be more readily available in border-
line cases. Mechanistically, the direct contact of
melanoma cells with upper layer keratinocytes
resulting from radial growth was shown to insti-
gate molecular interactions that trigger verti-
cal invasion by melanocytes.18 Indeed, many of
the genes recently associated with prognosis in
melanoma represent keratinocyte genes, which
may allude to an under-recognized importance
of the epidermal microenvironment.19 As such,
we hypothesized that the presence and num-
ber/density of epidermal mitoses may represent
another diagnostic clue in the assessment of bor-
derline melanocytic lesions.
Our findings show that epidermal mitoses are
more common and of higher density in straight-
forward malignant lesions as well as challenging
cases that are ultimately designated as malignant
compared with those straight away or ultimately
classified as benign. This difference in preva-
lence (77% vs. 25%, p= 0.0012 in straightfor-
ward; 67% vs. 17%, p= 0.059 in challenging) and
median EMD (0 vs. 0.04, p= 0.001 in straight-
forward; 0 vs. 0.04, p= 0.06 in challenging)
appears to be slightly stronger in straightfor-
ward lesions, as would be expected (Tables 2
and 3). Our studies confirm our impression
that even epidermal mitoses are not found in
the majority of even moderately and severely
dysplastic nevi (75% without EM), where no
dermal mitoses were found. In contrast, the
majority of melanomas had EM, while only 18%
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of melanomas had dermal mitoses, making this
histologic feature less useful (albeit more spe-
cific). In straightforward nevi and melanomas,
the presence of EM did not correlate with any
clinical factors, and there was no significant dif-
ference in the amount of chronic inflammation
in lesions with and without epidermal mitoses.
These data suggest that in neoplasms falling on
the dysplasia melanoma continuum, EM result
from tumor cell autonomous factors rather than
external ones.
When looking at the cohort of 30 chal-
lenging lesions, even after FISH and myPath
studies, 9 of 30 cases were given an expert
consensus designation of ambiguous. Of
the 21 remaining cases, EM was significantly
increased in favor-malignant cases compared
with favor-benign as described earlier. Mean-
while, only two of nine (22%) cases ultimately
called melanoma had dermal mitoses, rendering
this feature less applicable. The baseline clini-
copathologic features were comparable in all 30
cases, aside from histologic inflammation that
was significantly increased in the ambiguous and
favor-malignant lesions, compared with those
ultimately called benign (Table 3).
It bears deliberate discussion that Spitz lesions
confound the data with the largest number of
epidermal and dermal mitoses overall; and, as
with every other aspect of their analysis, should
be treated as their own entity. Spitz lesions are
increasingly proving to represent a genetically
and biologically unique group, as manifest by
their increased propensity to spread to regional
lymph nodes but be otherwise non-lethal for the
most part. Indeed, even dermal mitoses have
been previously described in non-malignant Spit-
zoid lesions7 and were noted in our study as well.
Our data support the tradition of allowing der-
mal mitoses in non-malignant Spitz tumors, and
show the same for epidermal mitoses.
While expert histologic diagnosis still
remains the gold standard for classifying
melanocytic lesions,20 the interobserver dis-
agreement rate is non-trivial21–23 and a subset
of cases are still interpreted as ambiguous.
Thus, objective molecular tests like FISH for
melanoma-associated genomic aberrations
or myPath gene expression score are being
developed to improve diagnostic accuracy. The
melanoma-FISH assay is better established,24 but
not perfect. It does not show a 100% correlation
with histologic diagnosis, but the pathologist
faced with a challenging melanocytic lesion is
hard-pressed not to interpret it as melanoma
in the presence of a positive FISH result. On
the other hand, as the assay covers only select
genomic loci, malignancy cannot be excluded
with a negative FISH result, but becomes less
probably. Concordantly, in our study, all the
lesions in the challenging group that were pos-
itive by melanoma-FISH were interpreted as
favor-malignant. The myPath gene expression
score assay also distinguishes between benign
andmalignant melanocytic lesions with reported
sensitivity and specificity comparable with those
of FISH.25 As a difference, myPath has the caveat
of an ‘indeterminate’ result category for a small
but significant fraction of cases. Furthermore,
our recent work revealed discordant results
between the two ancillary tests in a subset of
cases, especially challenging lesions, for which
unequivocal molecular results would be most
needed.26
We determined based on the straightforward
group of cases that an EMD cutoff of 0.01/mm
provides the best separation between benign and
malignant lesions, with a sensitivity and speci-
ficity non-inferior to themyPath gene expression
score. When applying this cutoff to the challeng-
ing group of cases, the sensitivity and specificity
were only marginally lower than in the straight-
forward group, and remained non-inferior to
the myPath score. While the overlap between
the presence or absence of epidermal mitoses
and a positive or negative myPath score was not
complete, the gene expression score results pro-
vides additional validation for the potential dis-
criminatory power of EMD between malignant
and benign lesions. It is indeed possible that the
myPath test includes a metric of genes expressed
during junctional melanocyte proliferation.
In the challenging group, there was an inter-
esting and significant increase in the proportion
of cases with inflammation from favor-benign
to ambiguous and to favor-malignant lesions
(Table 3). Inflammation may be regarded
as a response to an aggressive melanocytic
proliferation or mutation-associated neoanti-
gen expression. Conversely, it can be argued
that inflammation may induce secondary
melanocyte activation and proliferation,
resulting in increased mitoses, possibly a
modified molecular milieu and even skewing
of a gene expression-based test like myPath.26
Our results suggest that in straightforward
cases, inflammation is not confounding and
does not impact EM, but in borderline lesions
inflammation can confound interpretation. The
mechanisms by which inflammation influences
histologic and molecular melanocytic attributes
require further study.
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Our results additionally revealed a positive cor-
relation between EMD and Breslow’s thickness
in invasive melanomas, which was stronger in
straightforward lesions. This is not explained
simply by the overall size of the lesion, as EMD
is independent of lesion breadth, but is more
probably related to the biologic potential of the
malignancy, where an aggressive tumor has an
increased density of epidermal mitoses associ-
ated with a deeper dermal infiltration.
Evaluation of melanocytic lesions does not tra-
ditionally include an assessment of epidermal
mitoses. Here we show that the presence of epi-
dermal mitoses and EMD above 0.01/mm cor-
relate with a diagnosis of malignancy and with
the results of a molecular gene expression-based
test. While calculating a standard EMD may be
viewed as impractical and evaluation for epi-
dermal melanocytic mitoses is not adequate
as a single criterion in classifying melanocytic
lesions, our study suggests that the presence of
more than rare epidermal melanocytic mitoses
should be considered as favoring a malignant
diagnosis, and should prompt closer investi-
gation for malignancy. Further studies on an
expanded cohort with clinical follow-up are war-
ranted to further assess the diagnostic utility and
biologic significance of epidermal melanocytic
mitoses.
Supporting Information
Additional Supporting Informationmay be found in the online
version of this article:
Table S1. Clinicopathologic characteristics of the 46 straight-
forward cases in the study cohort.
Table S2. Clinicopathologic characteristics of the 30 challeng-
ing cases in the study cohort.
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